KR20090081813A - Island Yellow Stem Extract Indicating Anti-Allergy - Google Patents
Island Yellow Stem Extract Indicating Anti-Allergy Download PDFInfo
- Publication number
- KR20090081813A KR20090081813A KR1020080007893A KR20080007893A KR20090081813A KR 20090081813 A KR20090081813 A KR 20090081813A KR 1020080007893 A KR1020080007893 A KR 1020080007893A KR 20080007893 A KR20080007893 A KR 20080007893A KR 20090081813 A KR20090081813 A KR 20090081813A
- Authority
- KR
- South Korea
- Prior art keywords
- island
- extract
- stem
- yellow
- yellow wall
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000284 extract Substances 0.000 title claims abstract description 40
- 230000003266 anti-allergic effect Effects 0.000 title claims abstract description 11
- 238000000227 grinding Methods 0.000 claims abstract description 15
- 108010012236 Chemokines Proteins 0.000 claims abstract description 14
- 102000019034 Chemokines Human genes 0.000 claims abstract description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 14
- 102000004127 Cytokines Human genes 0.000 claims abstract description 12
- 108090000695 Cytokines Proteins 0.000 claims abstract description 12
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 12
- 238000001035 drying Methods 0.000 claims abstract description 10
- 208000026935 allergic disease Diseases 0.000 claims abstract description 9
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 9
- 238000004519 manufacturing process Methods 0.000 claims abstract description 7
- 239000000843 powder Substances 0.000 claims abstract description 7
- 238000002481 ethanol extraction Methods 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 239000000469 ethanolic extract Substances 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract description 21
- 201000008937 atopic dermatitis Diseases 0.000 abstract description 21
- 239000003814 drug Substances 0.000 abstract description 6
- 206010003645 Atopy Diseases 0.000 abstract description 5
- 208000037976 chronic inflammation Diseases 0.000 abstract description 5
- 230000006020 chronic inflammation Effects 0.000 abstract description 5
- 229940124597 therapeutic agent Drugs 0.000 abstract description 4
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 2
- 230000007815 allergy Effects 0.000 abstract description 2
- 208000017520 skin disease Diseases 0.000 abstract description 2
- 238000000338 in vitro Methods 0.000 abstract 1
- 230000003248 secreting effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 13
- 108090001007 Interleukin-8 Proteins 0.000 description 11
- 210000001616 monocyte Anatomy 0.000 description 10
- 102000004889 Interleukin-6 Human genes 0.000 description 9
- 108090001005 Interleukin-6 Proteins 0.000 description 9
- 230000000694 effects Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 238000012404 In vitro experiment Methods 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 210000003630 histaminocyte Anatomy 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 206010013786 Dry skin Diseases 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 241001247821 Ziziphus Species 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010066091 Bronchial Hyperreactivity Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000012085 chronic inflammatory response Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000006032 tissue transformation Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/17—Preparation or pretreatment of starting material involving drying, e.g. sun-drying or wilting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 항알러지를 나타내는 섬황벽 줄기 추출물에 관한 것으로서, 더욱 상세하게는 섬황벽 줄기(심재) 추출물을 통해 아토피 피부염에서 만성적인 염증을 유발시키는 염증성 사이토카인 및 케모카인의 생산을 억제할 수 있는 항알러지를 나타내는 섬황벽 줄기 추출물에 관한 것이다.The present invention relates to an anti-allergic island yellowish stem stem extract, and more particularly, an anti-allergic anti-allergic extract that can inhibit the production of inflammatory cytokines and chemokines that cause chronic inflammation in atopic dermatitis through the extract of heart yellow stem (heartwood). It is related to the island yellow wall stem extract which shows allergy.
본 발명의 섬황벽 줄기 추출물은,Island yellow wall stem extract of the present invention,
섬황벽 줄기를 말리는 건조단계와;Drying step of drying the island yellow wall stem;
건조된 줄기를 분말화시키는 분말화단계와;A powdering step of powdering the dried stems;
상기 분말화단계를 통해 제조된 섬황벽 줄기 분말을 0.5 Liter의 100% 에탄올로 추출하는 에탄올추출단계;를 통하여 제조된 추출물인 것을 특징으로 한다.Characterized in that the extract produced through the; ethanol extraction step of extracting the island yellow wall stem powder prepared by the powdering step with 100% ethanol of 0.5 Liter.
본 발명을 통해 섬황벽 줄기(심재) 추출물이 아토피 피부염에서 만성적인 염증을 유발시키는 염증성 사이토카인 및 케모카인의 생산을 억제함으로 다양한 세포주를 통한 생체 외 실험에서 확인된 이들 사이토카인 및 케모카인의 분비에 대한 뚜렷한 억제효과는 아토피 피부질환에 대한 치료제로써 유용하게 활용될 수 있게 되었다.Through the present invention, the island yellow wall stem (heartwood) extract inhibits the production of inflammatory cytokines and chemokines that cause chronic inflammation in atopic dermatitis, thereby secreting these cytokines and chemokines secreted in vitro through various cell lines. Significant inhibitory effect has been found to be useful as a therapeutic agent for atopic skin diseases.
Description
본 발명은 항알러지를 나타내는 섬황벽 줄기 추출물에 관한 것으로서, 더욱 상세하게는 섬황벽 줄기(심재) 추출물을 통해 아토피 피부염에서 만성적인 염증을 유발시키는 염증성 사이토카인 및 케모카인의 생산을 억제할 수 있는 항알러지를 나타내는 섬황벽 줄기 추출물에 관한 것이다.The present invention relates to an anti-allergic island yellowish stem stem extract, and more particularly, an anti-allergic anti-allergic extract that can inhibit the production of inflammatory cytokines and chemokines that cause chronic inflammation in atopic dermatitis through the extract of heart yellow stem (heartwood). It is related to the island yellow wall stem extract which shows allergy.
아토피성 피부염(atopic dermatitis)은 유전적, 환경적, 면역학적인 원인으로 피부 가장 바깥에 있는 보호벽인 각질층에 이상이 생긴 것으로 건조한 기후에서 더욱 심해지는 알레르기 질환이다. Atopic dermatitis is a genetic, environmental, and immunological cause of abnormalities in the stratum corneum, the outermost protective wall of the skin.
아토피성 피부염은 상당히 많은 사람들이 앓고 있는데, 전 인구의 0.5~1%, 어린이의 경우 5~10%가 아토피성 피부염으로 고통을 받고 있으며, 환자의 50%는 두 돌 이내에 치유되나 25%는 청소년기까지 가며, 나머지 25%는 성인이 되어서도 아토피 피부염이 없어지지 않고 계속된다.Atopic dermatitis suffers from a significant number of people, with 0.5 to 1 percent of the population and 5 to 10 percent of children suffering from atopic dermatitis. 50 percent of patients heal within two stones, but 25 percent of adolescents The remaining 25% will continue without atopic dermatitis even as adults.
아토피성 피부염의 주요증상은 심한 가려움증, 피부건조, 발진, 진물, 부스 럼딱지, 비늘 같은 껍질이 있는 피부(인비늘) 등이다.The main symptoms of atopic dermatitis are severe itching, dry skin, rashes, rash, crusts and scaly skin (in scales).
이러한 아토피성 피부염의 원인은 잘 알려져 있지 않으나 주로 유전적인 요소가 많고 면역 반응과 관련되어 있는 것으로 밝혀져 있으며, 그 외에 건조한 피부, 정상인에 비해 쉽게 피부 가려움증을 느끼는 특성, 세균ㆍ바이러스ㆍ곰팡이 등에 의한 감염, 정서적 요인, 환경적 요인 등이 서로 복합적으로 작용하여 일어나는 것으로 보인다.The cause of atopic dermatitis is not well known, but it has been found to be mainly related to genetic factors and immune responses. In addition, it is easy to feel skin itch compared to dry skin, normal people, and infections caused by bacteria, viruses, and fungi. This seems to be caused by a combination of factors, emotional factors and environmental factors.
따라서 아토피성 피부염에 효과가 있으면서도 부작용이 없는 새로운 아토피성 피부염 치료를 위한 조성물 개발이 요구되고 있다.Therefore, there is a need for the development of a composition for the treatment of atopic dermatitis, which has an effect on atopic dermatitis but has no side effects.
섬황벽이란 쌍떡잎식물 쥐손이풀목 운향과의 낙엽활엽교목으로서 섬황벽나무 또는 섬황경피라고도 한다.The island yellow wall is a deciduous broad-leaved arboreous tree with the dicotyledonous musculaceae.
상기 섬황벽은 해발 100~1,300m의 깊은 산속에서 자라며 높이는 10m 안팍이며 가지가 굵고 사방으로 퍼진 형상을 가지고 있다.The island yellow wall grows in the deep mountains of 100 ~ 1,300m above sea level, 10m in height, and has thick and branched branches.
나무껍질은 연한 회색이고 코르크층이 발달하여 깊게 갈라진 형상으로 하고 있으며 속껍질은 노란색을 띄고 있으며 열매와 나무껍질은 건위,정장,해독,이뇨,치질 등의 약재로 사용되고 있고 대한민국의 울릉도 및 일본 등지에 분포되어 있다.The bark is light gray, and the cork layer is developed to be deeply divided. The bark is yellow. Fruits and bark are used as medicines for health, suit, detoxification, diuresis and hemorrhoids. It is distributed.
그러나 섬황벽의 효능이 상기한 약재 이외에는 별다른 효과 보고는 아직 없으며, 이에 본 발명자는 새로운 아토피성 피부염 치료를 위한 물질을 연구해오던 중 섬황벽 추출물이 아토피 피부염에서 만성적인 염증을 유발하는 염증성 사이토카인 및 케모카인의 생산을 억제하여 아토피 피부염에 탁월한 효과가 있음을 확인하고 본 발명을 완성하게 되었다.However, there is no report on the efficacy of island yellow wall except for the above-mentioned medicinal herbs. Therefore, the present inventors have been studying a substance for treating atopic dermatitis. Inhibiting the production of chemokines confirmed that the excellent effect on atopic dermatitis and the present invention was completed.
따라서 본 발명은 상기와 같은 종래 기술의 문제점을 감안하여 제안된 것으로서, 본 발명의 목적은 아토피성 피부염에 효과가 탁월하면서도 부작용이 없는 식물 추출물을 유효성분으로 하는 아토피성 피부염 치료를 위한 조성물을 제공하는데 그 목적이 있다.Therefore, the present invention has been proposed in view of the problems of the prior art as described above, and an object of the present invention is to provide a composition for the treatment of atopic dermatitis, which has an excellent effect on atopic dermatitis and has no side effects as an active ingredient. Its purpose is to.
또한, 본 발명의 다른 목적은 아토피 및 아스마와 같은 알러지성 질환에 대한 항알러지를 나타내는 섬황벽 줄기 추출물을 제공하는데 있다.In addition, another object of the present invention to provide an extract of the island stem wall showing anti-allergic to allergic diseases such as atopy and asma.
본 발명이 해결하고자 하는 과제를 달성하기 위하여,In order to achieve the problem to be solved by the present invention,
본 발명의 일실시예에 따른 섬황벽 줄기 추출물은,Island yellow wall stem extract according to an embodiment of the present invention,
섬황벽 줄기를 말리는 건조단계와;Drying step of drying the island yellow wall stem;
건조된 줄기를 분말화시키는 분말화단계와;A powdering step of powdering the dried stems;
상기 분말화단계를 통해 제조된 섬황벽 줄기 분말을 0.5 Liter의 100% 에탄올로 추출하는 에탄올추출단계;를 통하여 추출되는 것을 특징으로 한다.It is characterized in that it is extracted through; ethanol extraction step of extracting the island yellow wall stem powder prepared by the powdering step with 100% ethanol of 0.5 Liter.
본 발명에 따른 섬황벽 줄기 추출물을 유효성분으로 함유하는 알러지성 질환 치료용 조성물을 통해 섬황벽 줄기(심재) 추출물이 아토피 피부염에서 만성적인 염 증을 유발시키는 염증성 사이토카인 및 케모카인의 생산을 억제함으로 다양한 세포주를 통한 생체 외 실험에서 확인된 이들 사이토카인 및 케모카인의 분비에 대한 뚜렷한 억제효과는 아토피 피부질환에 대한 치료제로써 유용하게 활용될 수 있게 되었다.By inhibiting the production of inflammatory cytokines and chemokines that cause chronic inflammation in atopic dermatitis through the composition for the treatment of allergic diseases containing the island yellow wall stem extract according to the present invention as an active ingredient The apparent inhibitory effect on the secretion of these cytokines and chemokines confirmed in vitro experiments with various cell lines can be useful as a therapeutic agent for atopic skin diseases.
또한, 아토피 및 아스마와 같은 알러지성 질환에 대한 항알러지를 나타내는 섬황벽 줄기 추출물을 제공된다.Also provided are island stem wall extracts that exhibit anti-allergy against allergic diseases such as atopy and asma.
상기 과제를 달성하기 위한 본 발명의 일실시예에 따른 섬황벽 줄기 추출물은,Island yellow wall stem extract according to an embodiment of the present invention for achieving the above object,
섬황벽 줄기를 말리는 건조단계와;Drying step of drying the island yellow wall stem;
건조된 줄기를 분말화시키는 분말화단계와;A powdering step of powdering the dried stems;
상기 분말화단계를 통해 제조된 섬황벽 줄기 분말을 0.5 Liter의 100% 에탄올로 추출하는 에탄올추출단계;를 통하여 제조하는 것으로 구성된다.The ethanol extraction step of extracting the island yellow wall stem powder prepared through the powdering step with 100% ethanol of 0.5 Liter;
또한, 상기 섬황벽 줄기(심재) 추출물을 유효성분으로 함유하는 알러지성 질환 치료용 조성물을 제공하게 된다.In addition, to provide a composition for treating allergic diseases containing the island yellow wall stem (heartwood) extract as an active ingredient.
본 발명의 조성물에 사용되는 섬황벽을 분말화하거나 추출물을 제조하여 사용할 수 있다.The island yellow wall used in the composition of the present invention may be powdered or an extract may be used.
상기 추출은 열탕추출, 소니케이션 등 통상의 방법으로 수행할 수 있으며, 이 추출물의 동결건조물을 형성하여 본 발명의 조성물에 사용할 수도 있다. The extraction may be carried out by a conventional method such as hot water extraction, sonication, and can also be used in the composition of the present invention by forming a lyophilisate of the extract.
즉, 섬황벽 줄기를 말리는 건조단계와;That is, the drying step of drying the island yellow wall stem;
건조된 줄기를 분말화시키는 분말화단계와;A powdering step of powdering the dried stems;
상기 분말화단계를 통해 제조된 섬황벽 줄기 분말을 0.5 Liter의 100% 에탄올로 추출하는 에탄올추출단계;를 통하여 추출물을 획득할 수 있는데, 바람직하게는 가루화한 섬황벽 30g을 0.5 Liter의 100% 에탄올로 24시간동안 추출하고, 이러한 방법을 3회 실시하여 획득하게 된다.An ethanol extraction step of extracting the yellowish yellow stem stem powder prepared through the powdering step with 0.5 Liter of 100% ethanol; can be obtained through the extraction, preferably 30g of the powdered yellowish
또한, 다른 추출 방법으로 가루로 만든 섬황벽 30g을 100%에탄올 (3×0.5L)로 이틀 동안 실온에서 추출하여 획득할 수도 있다.Alternatively, 30 g of the islands's yellow walls, made from powder, can be obtained by extraction with 100% ethanol (3 x 0.5 L) at room temperature for two days.
또한 상기 추출물은 통상의 분획법 또는 크로마토그라피에 의해 보다 정제하여 사용할 수 있으며, 이러한 분획물 또는 정제물이 본 발명의 범위에 속함은 물론이다.In addition, the extract can be used more purified by a conventional fractionation method or chromatography, these fractions or purified products are of course within the scope of the present invention.
본 발명의 조성물은 약제학적 분야에서 공지의 방법에 의해 제제화할 수 있고, 추출물 자체 또는 약제학적으로 허용되는 담체, 부형제 등과 혼합하여 통상의 약학적 제제, 예를 들면 액제, 시럽제, 캡슐제, 과립제, 분말, 연고, 에멀젼, 겔, 크림 등으로 제제화할 수 있으며, 이를 여러 경로로 투여할 수 있다.The compositions of the present invention may be formulated by methods known in the pharmaceutical art, and may be mixed with the extracts themselves or with pharmaceutically acceptable carriers, excipients, and the like, to form conventional pharmaceutical preparations such as liquids, syrups, capsules, and granules. , Powders, ointments, emulsions, gels, creams, and the like, which can be administered by several routes.
본 발명의 조성물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. Preferred dosages of the compositions of the present invention vary depending on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art.
이하, 본 발명을 하기 실시예 및 실험예에 의하여 보다 구체적으로 설명하지만, 이들에 의하여 본 발명의 범위가 어떤 식으로든 제한되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to the following Examples and Experimental Examples, but the scope of the present invention is not limited by them in any way.
본 발명에서 설명하고 있는 케모카인은 다양한 종류의 백혈구의 이동과 활성화를 조절하는 사이토카인으로 조직으로의 염증세포의 침윤을 조절한다. The chemokine described in the present invention is a cytokine that regulates the movement and activation of various types of white blood cells, and regulates infiltration of inflammatory cells into tissues.
MCP-1 (monocyte chemoattractent protein -1)은 단핵구, 활성화된 T 세포, 자연살해세포, 미성숙 수상돌기세포 등에서 분비되며, 섬유모세포의 콜라젠을 과발현시켜 섬유화를 유발하는 요인이 된다. MCP-1 (monocyte chemoattractent protein-1) is secreted from monocytes, activated T cells, natural killer cells, immature dendritic cells, etc., and causes fibrosis by overexpressing collagen of fibroblasts.
또한, 다양한 염증성 질환의 염증 부위에 단핵구를 끌어들이고 이를 통해 염증세포를 제거한다. 그러나, 과량의 MCP-1의 분비는 오히려 만성적인 염증반응을 초래한다. In addition, monocytes are attracted to the site of inflammation of various inflammatory diseases, thereby removing inflammatory cells. However, excessive secretion of MCP-1 results in a chronic inflammatory response.
만성 염증성 반응에서 다양한 세포를 활성화시키는 IL-6의 분비를 증가시켜 많은 섬유모세포의 분화와증식을 초래하며, 세포외 기질(extra cellular matrix)의 생산을 과생산하여 세포 및 조직의 변형과 섬유화를 야기시킨다.Increases the secretion of IL-6, which activates various cells in chronic inflammatory reactions, resulting in differentiation and proliferation of many fibroblasts, and overproduction of extracellular matrix to alter cell and tissue transformation and fibrosis Cause.
IL-8은 초기염증반응에 중요하고 기도상피세포에서 분비되는 중요한 염증성 케모카인으로서, IL-8에 의해 기관지과민성이 유발되고 알레르기비염이나 기관지천식에서 증가되어 있으며 IL-8은 스테로이드에 의해 억제된다. IL-8 is an important inflammatory chemokine secreted by airway epithelial cells that is important for early inflammatory reactions. It is caused by bronchial hypersensitivity by IL-8 and is increased in allergic rhinitis or bronchial asthma and IL-8 is inhibited by steroids.
본 발명에서는 아토피 피부염에 관여하는 단핵구에서 염증성 케모카인 및 사이토카인인 MCP-1, IL-6, IL-8 에 대해 섬황벽 줄기(심재)의 효과를 검증한 것이다. In the present invention, the effect of the island wall against the inflammatory chemokine and cytokines MCP-1, IL-6, IL-8 in monocytes involved in atopic dermatitis was verified.
<실시예> THP-1 세포 배양EXAMPLES THP-1 Cell Culture
사람의 단핵구(monocyte)인 THP-1(human acute monocytic leukemia cell : 미국세포주은행)를 2.0 x 105/m로 RPMI 1640 배지, antibiotics(penicillinm 104 U/ml, streptomycin 10 mg/ml, amphotericin B 25 μg/ml)과 10% FBS를 넣고 37℃ CO2 배양기에서 3일간 배양하였다.Human monocyte (THP-1) (human acute monocytic leukemia cell, US Cell Line Bank) at 2.0 x 105 / m RPMI 1640 medium, antibiotics (penicillinm 104 U / ml,
<실시예2> MCP-1, IL-6, IL-8 측정Example 2 MCP-1, IL-6, IL-8 Measurement
THP-1 세포를 0.5%FBS가 든 RPMI에 2.0 X 106/m로 24 well plate에 분주한 후 배양기(37℃, 5%CO2)에서 16시간 배양하였다.THP-1 cells were dispensed in 24 well plates at 2.0 X 106 / m in RPMI containing 0.5% FBS and incubated for 16 hours in an incubator (37 ° C, 5% CO2).
배양후 섬황벽 줄기(심재) 추출물(최종 농도 1μg/ml, 10μg/ml, 50μg/ml)을 1시간 동안 처리한 후 HDE(1μg/ml)를 각각 24시간동안 처리한 다음 ELISA를 이용하여 상층액에서 MCP-1(monocyte chemoattractent protein -1), IL-6, IL-8의 양을 측정하였다.After cultivation, the island yellow wall stem (heartwood) extract (final concentration 1μg / ml, 10μg / ml, 50μg / ml) was treated for 1 hour, followed by HDE (1μg / ml) for 24 hours, respectively, followed by upper layer using ELISA. The amount of MCP-1 (monocyte chemoattractent protein-1), IL-6, and IL-8 in the fluid was measured.
도 1은 본 발명의 조성물 투여시 MCP-1을 측정한 결과를 나타낸 그래프이다.1 is a graph showing the results of measuring MCP-1 upon administration of the composition of the present invention.
도 1를 참조하여 설명하자면, THP-1(사람의 단핵구세포)에 Mite (1ug/ml)를 처리하면 MCP-1이 분비되는데, THP-1에 섬황벽 줄기(심재) 추출물을 1, 10, 50 ug/ml 로 각각 처리한 후, 1시간 뒤 mite 로 활성화시켜 24시간 뒤 ELISA를 이용하여 상층액에서 MCP-1을 측정한 결과 농도의존적으로 MCP-1의 분비가 억제되는 것을 확인할 수 있었다.Referring to Figure 1, when treated with Mite (1ug / ml) to THP-1 (monocytes in humans), MCP-1 is secreted. After treatment with 50 ug / ml each, after 1 hour activating with mite and after 24 hours by measuring the MCP-1 in the supernatant using ELISA, it was confirmed that the secretion of MCP-1 is suppressed in a concentration-dependent manner.
도 2는 본 발명의 조성물 투여시 IL-6을 측정한 결과를 나타낸 그래프이다.Figure 2 is a graph showing the results of measuring IL-6 upon administration of the composition of the present invention.
또한, 도 2를 참조하여 설명하자면, THP-1(사람의 단구세포)에 Mite (1ug/ml)를 처리하면 IL-6이 분비되는데, THP-1에 섬황벽 줄기(심재) 추출물을 1, 10, 50 ug/ml 로 각각 처리한 후, 1시간 뒤 mite 로 활성화시켜 24시간 뒤 ELISA를 이용하여 상층액에서 IL-6을 측정한 결과 농도의존적으로 IL-6의 분비가 억제되는 것을 확인할 수 있었다.In addition, referring to Figure 2, when treated with Mite (1ug / ml) to THP-1 (monocytes in humans) secreted IL-6, THP-1 to the island of the yellow wall stem (heartwood)
도 3은 본 발명의 조성물 투여시 IL-8을 측정한 결과를 나타낸 그래프이다.Figure 3 is a graph showing the results of measuring IL-8 upon administration of the composition of the present invention.
또한, 도 3을 참조하여 설명하자면, THP-1(사람의 단구세포)에 Mite (1ug/ml)를 처리하면 IL-8이 분비되는데, THP-1에 섬황벽 줄기(심재) 추출물을 1, 10, 50 ug/ml 로 각각 처리한 후, 1시간 뒤 mite 로 활성화시켜 24시간 뒤 ELISA를 이용하여 상층액에서 IL-8을 측정한 결과 농도의존적으로 IL-8의 분비가 억제되는 것을 알 수 있었다.In addition, referring to Figure 3, when treated with Mite (1ug / ml) to THP-1 (monocytes in humans) secreted IL-8, THP-1 to the island of the yellow wall stem (heartwood)
도 4는 본 발명의 조성물 투여시 비만세포주인 HMC-1 세포 생장율을 측정한 결과를 나타낸 그래프이다.Figure 4 is a graph showing the results of measuring the growth rate of HMC-1 cell mast cells when the composition of the present invention.
도 4를 참조하여 설명하자면, 섬황벽 줄기(심재) 추출물을 비만세포주인 HMC-1 세포에 1~10 mg/ml로 처리한 후 24시간 뒤 MTT assay를 이용하여 세포 생장율 측정 결과 1~10 mg/ml의 섬황벽 줄기(심재) 추출물에서 세포의 생장을 억제하는 독성을 나타내지 않음을 알 수 있었다.Referring to Figure 4, after treatment of the island stem wall (heartwood) extract to the mast cell line HMC-1
도 5는 본 발명의 조성물 투여시 Stem cell factor에 의한 HMC-1 세포의 유주 운동의 억제 효과를 나타낸 그래프이다.5 is a graph showing the inhibitory effect of jujube movement of HMC-1 cells by Stem cell factor upon administration of the composition of the present invention.
도 5는 Stem cell factor에 의한 HMC-1세포의 유주운동에 있어서 섬황벽 줄기(심재)의 추출물의 억제효과를 확인한 실험으로서 섬황벽 줄기(심재)의 추출물을 1-10 mg /ml의 농도에서 24시간동안 처리했으며, 대조군을 100%로 했을 때, 농도에 의존하여 억제효과를 보여주었다.5 is an experiment confirming the inhibitory effect of the extract of the island yellow wall stem (heartwood) in the movement of HMC-1 cells by Stem cell factor at a concentration of 1-10 mg / ml Treatment was performed for 24 hours, and when the control group was 100%, the inhibitory effect was shown depending on the concentration.
따라서, 도 4 내지 도 5는 천식을 유발시키는 원인 세포중의 하나인 비만세포에 대하여 섬황벽 줄기(심재) 추출물의 효과를 in vitro (생체 외) 실험을 한 것 으로서, stem cell factor에 의한 비만세포(HMC-1)의 유주성(이동)에 대하여 섬황벽 줄기(심재) 추출물이 억제효과가 있었고, 이를 통하여 알레르기 질환에 대한 치료효과의 가능성이 있음을 확인할 수 있었다.Therefore, FIGS. 4 to 5 are in vitro experiments on the effects of extracts of the island wall against heart cells, one of the causative agents of asthma, and are characterized by obesity caused by stem cell factors. The island yellow wall stem (heartwood) extract had an inhibitory effect on the chemotaxis (migration) of the cells (HMC-1).
본 발명을 통해 아토피 피부염에 관여하는 단핵구에서 염증성 chemokine 및 사이토카인인 MCP-1, IL-6, IL-8에 대하여 섬황벽 줄기(심재)가 억제 효과가 있음을 알 수 있었으며 이를 통해 섬황벽 줄기가 아토피 피부염에 대한 새로운 치료제로써 유용하게 활용될 수 있는 가능성을 나타내었다.Through the present invention, it was found that the island yellow wall stem (heartwood) has an inhibitory effect on the inflammatory chemokine and cytokines MCP-1, IL-6, and IL-8 in monocytes involved in atopic dermatitis. Has been shown to be useful as a new therapeutic agent for atopic dermatitis.
이상에서와 같은 내용의 본 발명이 속하는 기술분야의 당업자는 본 발명의 기술적 사상이나 필수적 특징을 변경하지 않고서 다른 구체적인 형태로 실시될 수 있다는 것을 이해할 수 있을 것이다. 그러므로 이상에서 기술한 실시 예들은 모든 면에서 예시된 것이며 한정적인 것이 아닌 것으로서 이해해야만 한다. Those skilled in the art to which the present invention pertains as described above may understand that the present invention may be implemented in other specific forms without changing the technical spirit or essential features of the present invention. Therefore, the above-described embodiments are to be understood as illustrative in all respects and not restrictive.
본 발명의 범위는 상기 상세한 설명보다는 후술하는 특허청구범위에 의하여 나타내어지며, 특허청구 범위의 의미 및 범위 그리고 그 등가 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.The scope of the invention is indicated by the following claims rather than the above description, and all changes or modifications derived from the meaning and scope of the claims and their equivalents should be construed as being included in the scope of the invention. do.
본 발명인 섬황벽 줄기 추출물은 섬황벽 줄기(심재) 추출물이 아토피 피부염에서 만성적인 염증을 유발시키는 염증성 사이토카인 및 케모카인의 생산을 억제함으로 다양한 세포주를 통한 생체 외 실험에서 확인된 이들 사이토카인 및 케모카인 의 분비에 대한 뚜렷한 억제효과는 아토피 피부질환에 대한 치료제로써 유용하게 활용될 수 있게 되어 아토피 피부염 치료 분야에 널리 활용될 것이다.The present invention of the island yellow wall stem extracts of these cytokines and chemokines confirmed in vitro experiments through various cell lines by the island yellow wall stem (heartwood) extract inhibits the production of inflammatory cytokines and chemokines that cause chronic inflammation in atopic dermatitis A clear inhibitory effect on the secretion will be useful as a therapeutic agent for atopic dermatological diseases will be widely used in the field of atopic dermatitis.
도 1은 본 발명의 조성물 투여시 MCP-1을 측정한 결과를 나타낸 그래프이다.1 is a graph showing the results of measuring MCP-1 upon administration of the composition of the present invention.
도 2는 본 발명의 조성물 투여시 IL-6을 측정한 결과를 나타낸 그래프이다.Figure 2 is a graph showing the results of measuring IL-6 upon administration of the composition of the present invention.
도 3은 본 발명의 조성물 투여시 IL-8을 측정한 결과를 나타낸 그래프이다.Figure 3 is a graph showing the results of measuring IL-8 upon administration of the composition of the present invention.
도 4는 본 발명의 조성물 투여시 비만세포주인 HMC-1 세포 생장율을 측정한 결과를 나타낸 그래프이다.Figure 4 is a graph showing the results of measuring the growth rate of HMC-1 cell mast cells when the composition of the present invention.
도 5는 본 발명의 조성물 투여시 Stem cell factor에 의한 HMC-1 세포의 유주 운동의 억제 효과를 나타낸 그래프이다.5 is a graph showing the inhibitory effect of jujube movement of HMC-1 cells by Stem cell factor upon administration of the composition of the present invention.
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020080007893A KR20090081813A (en) | 2008-01-25 | 2008-01-25 | Island Yellow Stem Extract Indicating Anti-Allergy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020080007893A KR20090081813A (en) | 2008-01-25 | 2008-01-25 | Island Yellow Stem Extract Indicating Anti-Allergy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20090081813A true KR20090081813A (en) | 2009-07-29 |
Family
ID=41293042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020080007893A Ceased KR20090081813A (en) | 2008-01-25 | 2008-01-25 | Island Yellow Stem Extract Indicating Anti-Allergy |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20090081813A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012081776A1 (en) * | 2010-12-16 | 2012-06-21 | Yd Life Science Co., Ltd | Composition comprising an extract of phellodendri cortex for the prevention or treatment of pancreatitis. |
-
2008
- 2008-01-25 KR KR1020080007893A patent/KR20090081813A/en not_active Ceased
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012081776A1 (en) * | 2010-12-16 | 2012-06-21 | Yd Life Science Co., Ltd | Composition comprising an extract of phellodendri cortex for the prevention or treatment of pancreatitis. |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102445516B1 (en) | Composition for skin improvement comprising exosomes derived from ginseng plant cells as an active ingredient | |
| Shin et al. | Preventive effects of skullcap (Scutellaria baicalensis) extract in a mouse model of food allergy | |
| KR101567633B1 (en) | Composition for treatment or prevention of inflammatory skin diseases comprising unripe Citurs unshiu extract, or synephrine or salts thereof | |
| KR20180128602A (en) | Composition for preventing, improving or treating atopic dermatitis comprising juice of radish root as effective component | |
| KR101873218B1 (en) | Composition for alleviating skin irritation and skin inflammation induced by particulate matter comprising extracts mixture of Ocimum sanctum, Mentha haplocalyx, and Azadirachta indica | |
| KR101367423B1 (en) | Pharmaceutical composition and cosmetic compostion for improving skin condition and preparation method thereof | |
| KR101262813B1 (en) | The composition comprising picrasma quassioides extract for preventing and treating atopic dermatitis or allergic skin diseases | |
| KR101497276B1 (en) | A pharmaceutical composition comprising herbal extracts for prevention and treatment of arthritis and herniation of intervertebral discs | |
| KR100772575B1 (en) | Skin external composition containing herbal extract | |
| KR102002894B1 (en) | Cosmetic composition containing the complex natural extracts | |
| KR102150927B1 (en) | Cosmetic and pharmaceutical compositin comprising sasa quelpaertensis extract and urea | |
| WO2019132625A1 (en) | Composition for preventing, improving or treating atopic dermatitis containing mixed herbal extract as active ingredient | |
| CN107920974A (en) | Cosmetic composition for suppressing pruritus and improving atopic dermatitis containing active ingredient ISTP | |
| KR101698869B1 (en) | A composition for treatment of Atopic dermatitis containing oriental medicine herbs | |
| KR102261340B1 (en) | A composition comprising extract of Prasiola japonica for preventing or treating for inflammatory skin diseases | |
| KR20210053575A (en) | Composition for preventing and treating allergy comprising asiatic tearthumb | |
| KR102248259B1 (en) | Composition for skin improvement comprising Soybean plant cell-derived exosomes as an active ingredient | |
| KR102127771B1 (en) | A composition for antioxidation, anti-inflammation, antiaging or skin soothing comprising herb complex extracts | |
| KR20090081813A (en) | Island Yellow Stem Extract Indicating Anti-Allergy | |
| KR101746158B1 (en) | Composition for ameliorating atopic dermatitis comprising Gypsophila oldhamiana extract and use thereof | |
| CN104394867B (en) | Containing purine derivative or the compositions for preventing or treat allergic dermatitis of its salt | |
| JP6080479B2 (en) | Preventive and therapeutic agent for herpes simplex virus infection derived from maitake extract | |
| KR102506493B1 (en) | Composition for preventing or treating edema comprising Prasiola japonica extract or fraction thereof as active ingredient | |
| KR101707107B1 (en) | Composition for multi-functional activation comprising Liquiritigenin | |
| KR102790058B1 (en) | Composition for preventing, ameliorating or treating rosacea comprising Artemisia sp. plant extracts as an active ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20080125 |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20091118 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20100303 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20091118 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |